Select country set
Menu Shopping cart 0,00 Search
Manufactured by BioVendor

hsa-miR-145-5p miREIA

  • Regulatory status:RUO
  • Type:miREIA – miRNA enzyme immunoassay
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price

RDM0003H 96 wells (1 kit)
PubMed Product Details
Technical Data


miREIA – miRNA enzyme immunoassay


Whole blood

Sample Requirements

10 µl/well


At ambient temperature. Upon receipt, store the product at the temperature recommended below.


Store the complete kit at 2 – 8 °C. Under these conditions, all components are stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

12.5 – 0.39 amol/μl

Limit of Detection

0.13 amol/μl

Intra-assay (Within-Run)

n = 8,
CV = 3.1%

Inter-assay (Run-to-Run)

n = 5,
CV = 6.7%

Spiking Recovery


Dilution Linearity



Crossreactivity with the miRNA family members exhibiting high sequence identity cannot be excluded.


Product Manual: miREIA - microRNA enzyme immunoassay

Have you bought miREIA kits and need help with assay procedure? Please look at product manual video how easy using the miREIA method is.

Product Manual: miREIA - microRNA enzyme immunoassay



Exact inter-species homology was found for example for:

Bornean orangutan
Brown anole
Brown bat
Carolina anole
King cobra
Short-tailed opossum
Western gorilla
Wild boar


  • It is intended for research use only
  • The total assay time is less than 2.5 hours
  • The kit measures hsa-miR-145-5p isolated from human blood
  • Assay format is 96 wells
  • Standard is synthetic miRNA-based
  • Components of the kit are provided ready to use, concentrated or dried

Research topic

Cardiovascular disease, Oncology


MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.

miR-145-5p is considered a member of the p53-tumor suppressor network and has been found to act as a post-transcriptional regulator of many cancer-related genes. Deregulations of miR-145-5p were observed in various types of human cancer including renal cancer, colorectal cancer, bladder cancer, lung cancer, glioblastoma and prostate cancer.

miR-145-5p is also involved in pathology of cardiovascular disease. miR-145-5p plasma levels were reported to be significantly lower in patients with acute myocardial infarction compared to healthy control group. Increased plasma levels of miR-145-5p were found in population with genetic predisposition to familiar dilated cardiomyopathy.

miR-145-5p is associated also with cerebral ischemia, where expression was significally higher in ischemic stroke patients when compare to control subjects.

Summary References (9)

References to miR-145-5p

  • Papadopoulos, Emmanuel I., et al. "Clinical evaluation of microRNA-145 expression in renal cell carcinoma: a promising molecular marker for discriminating and staging the clear cell histological subtype." Biological chemistry 397.6 (2016): 529-539.
  • Li, Jialu, et al. "Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma." Scientific reports 5 (2015): 12921.
  • Inamoto, Teruo, et al. "A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder." Disease Markers 2018 (2018).
  • Zhang, Hui, et al. "Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer." Oncology letters 13.2 (2017): 669-676.
  • Zhao, Hua, et al. "Serum microRNA profiling in patients with glioblastoma: a survival analysis." Molecular cancer 16.1 (2017): 59.
  • Goto, Yusuke, et al. "Impact of novel miR-145-3p regulatory networks on survival in patients with castration-resistant prostate cancer." British journal of cancer 117.3 (2017): 409.
  • Zhang, Ming, et al. "Circulating MicroRNA-145 is associated with acute myocardial infarction and heart failure." Chinese medical journal 130.1 (2017): 51.
  • Toro, Rocío, et al. "Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy." Journal of Molecular Medicine 96.8 (2018): 845-856
  • Gan, C. S., C. W. Wang, and K. S. Tan. "Circulatory microRNA-145 expression is increased in cerebral ischemia." Genet Mol Res 11.1 (2012): 147-152.
Related Products Docs